- Home
- PULM vs DALN Comparison
PULM vs DALN Comparison
Compare PULM & DALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- DALN
- Stock Information
- Founded
- PULM 2003
- DALN 1954
- Country
- PULM United States
- DALN United States
- Employees
- PULM N/A
- DALN N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- DALN Newspapers/Magazines
- Sector
- PULM Health Care
- DALN Consumer Discretionary
- Exchange
- PULM Nasdaq
- DALN Nasdaq
- Market Cap
- PULM 33.2M
- DALN 38.1M
- IPO Year
- PULM N/A
- DALN 2008
- Fundamental
- Price
- PULM $6.94
- DALN $4.42
- Analyst Decision
- PULM
- DALN
- Analyst Count
- PULM 0
- DALN 0
- Target Price
- PULM N/A
- DALN N/A
- AVG Volume (30 Days)
- PULM 62.8K
- DALN 24.0K
- Earning Date
- PULM 08-12-2025
- DALN 07-29-2025
- Dividend Yield
- PULM N/A
- DALN N/A
- EPS Growth
- PULM N/A
- DALN N/A
- EPS
- PULM N/A
- DALN 5.55
- Revenue
- PULM $1,921,000.00
- DALN $123,414,000.00
- Revenue This Year
- PULM N/A
- DALN N/A
- Revenue Next Year
- PULM $134.88
- DALN N/A
- P/E Ratio
- PULM N/A
- DALN $0.77
- Revenue Growth
- PULM N/A
- DALN N/A
- 52 Week Low
- PULM $1.78
- DALN $2.98
- 52 Week High
- PULM $10.40
- DALN $7.86
- Technical
- Relative Strength Index (RSI)
- PULM 42.62
- DALN 59.75
- Support Level
- PULM $6.36
- DALN $4.02
- Resistance Level
- PULM $7.99
- DALN $4.60
- Average True Range (ATR)
- PULM 0.90
- DALN 0.36
- MACD
- PULM -0.24
- DALN 0.04
- Stochastic Oscillator
- PULM 50.16
- DALN 57.89
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.